-
1.发明申请METHODS OF USING GENETIC VARIANTS TO DIAGNOSE AND PREDICT INFLAMMATORY BOWEL DISEASE 审中-公开使用遗传变异体进行诊断和预防炎症性皮肤疾病的方法公开(公告)号：US20100240043A1
公开(公告)日：2010-09-23
申请号：US12675718
申请日：2008-10-20
申请人： Jerome I. Rotter , Kent D. Taylor , Stephan R. Targan , Dermot P. McGovern , Ling Mei , Xiaowen Su
发明人： Jerome I. Rotter , Kent D. Taylor , Stephan R. Targan , Dermot P. McGovern , Ling Mei , Xiaowen Su
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The present invention relates to methods of diagnosing susceptibility to Inflammatory Bowel Disease and subtypes of Inflammatory Bowel Disease. In one embodiment, the present invention provides a method of diagnosing susceptibility to Inflammatory Bowel Disease by determining the presence of one or more risk variants at the DR3 locus, GATA3 locus, SIN(EFS) locus, BTLA locus, LIGHT locus and MAGE locus.
摘要翻译： 本发明涉及诊断易感性肠炎和炎症性肠病亚型的易感性的方法。 在一个实施方案中，本发明提供了通过确定在DR3基因座，GATA3基因座，SIN（EFS）基因座，BTLA基因座，LIGHT基因座和MAGE基因座处存在一种或多种风险变体来诊断易感性肠炎易感性的方法。
-
2.发明申请公开(公告)号：US20110177969A1
公开(公告)日：2011-07-21
申请号：US13121929
申请日：2009-10-01
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to methods of diagnosing susceptibility to Crohn's Diseaese by determining the presence or absence of susceptibility variants at the IL17RD locus. in one embodiment, the present invention provides a method of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4, where the presence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4 is indicative of susceptibility to Crohn's Disease.
摘要翻译： 本发明涉及通过测定IL17RD基因座上易感性变体的存在或不存在来诊断对克罗恩病的易感性的方法。 在一个实施方案中，本发明提供了诊断和/或预测对克罗恩病的易感性的方法，其通过确定IL17RD Block 2单倍型2和IL23R Block 2单倍型2和/或IL12RB2单倍型4之间存在或不存在相互作用，其中 IL17RD Block 2单倍型2和IL23R Block 2之间的相互作用存在单倍型2和/或IL12RB2单倍型4表示对克罗恩病的易感性。
-
3.发明申请METHODS OF PREDICTING MEDICALLY REFRACTIVE ULCERATIVE COLITIS (MR-UC) REQUIRING COLECTOMY 有权预防药物回顾性检查（MR-UC）的方法公开(公告)号：US20120053131A1
公开(公告)日：2012-03-01
申请号：US13140874
申请日：2009-12-24
申请人： Jerome I. Rotter , Kent D. Taylor , Stephan R. Targan , Talin Haritunians , Dermot P. McGovern , Xiuqing Guo
发明人： Jerome I. Rotter , Kent D. Taylor , Stephan R. Targan , Talin Haritunians , Dermot P. McGovern , Xiuqing Guo
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , G01N2800/067
摘要： Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis. In another embodiment, the severe form of ulcerative colitis is indicative of MR-UC.
摘要翻译： 公开了预测患者中医学难治性溃疡性结肠炎（MR-UC）的发展的方法。在一个实施方案中，公开了通过确定一种或多种风险变异体的存在或不存在来预测个体中溃疡性结肠炎的方法，其中 一种或多种风险变体的存在表示严重和/或侵略性形式的溃疡性结肠炎。 在另一个实施方案中，严重形式的溃疡性结肠炎指示MR-UC。
-
公开(公告)号：US20140017711A1
公开(公告)日：2014-01-16
申请号：US14007381
申请日：2012-03-26
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , C12Q1/6883 , C12Q2600/156 , G01N33/564 , G01N2800/065 , G01N2800/54 , G01N2800/56
摘要： The present invention relates to methods of prognosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of risk serological marker ANCA is indicative of an aggressive form of ulcerative colitis. In another embodiment, the present invention relates to methods of diagnosing a Crohn's disease subtype in an individual, where the presence of risk variants and serological markers I2, OmpC and/or Cbir1 are indicative of the Crohn's disease subtype.
摘要翻译： 本发明涉及通过确定存在至少一种风险遗传变异体和/或至少一种风险血清学标记物来预测个体中炎症性肠病（IBD）的方法。 在一个实施方案中，风险血清学标记ANCA的存在表示侵略性形式的溃疡性结肠炎。 在另一个实施方案中，本发明涉及在个体中诊断克罗恩病亚型的方法，其中存在风险变体和血清学标志物I2，OmpC和/或Cbir1表示克罗恩氏病亚型。
-
5.发明申请公开(公告)号：US20130136720A1
公开(公告)日：2013-05-30
申请号：US13521622
申请日：2011-01-14
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/172
摘要： The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the FUT2 genetic locus.
摘要翻译： 本发明涉及克罗恩病的预后，诊断和治疗。 本发明还提供了基于在FUT2遗传基因座处存在一种或多种遗传危险因素的预后，诊断和治疗。
-
6.发明申请METHODS OF DIAGNOSING AND TREATING INTESTINAL GRANULOMAS AND LOW BONE DENSITY IN INFLAMMATORY BOWEL DISEASE 审中-公开诊断和治疗炎症性皮肤病的骨质疏松和低密度的方法公开(公告)号：US20140018447A1
公开(公告)日：2014-01-16
申请号：US14007391
申请日：2012-03-26
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , G01N33/6893 , G01N2800/065
摘要： The present invention relates to methods of diagnosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of at least one risk genetic variant is indicative of granuloma. In another embodiment, the presence of at least one risk genetic variant is indicative of low bone density (LBD).
摘要翻译： 本发明涉及通过确定至少一种风险遗传变异体和/或至少一种风险血清学标记物的存在来诊断个体中炎症性肠病（IBD）的方法。 在一个实施方案中，至少一种风险遗传变异体的存在是肉芽肿的指示。 在另一个实施方案中，存在至少一种风险遗传变体表示低骨密度（LBD）。
-
7.发明授权Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy 有权预测需要结肠切除术的医疗屈光性溃疡性结肠炎（MR-UC）的方法公开(公告)号：US09580752B2
公开(公告)日：2017-02-28
申请号：US13140874
申请日：2009-12-24
申请人： Jerome I. Rotter , Kent D. Taylor , Stephan R. Targan , Talin Haritunians , Dermot P. McGovern , Xiuqing Guo
发明人： Jerome I. Rotter , Kent D. Taylor , Stephan R. Targan , Talin Haritunians , Dermot P. McGovern , Xiuqing Guo
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , G01N2800/067
摘要： Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis. In another embodiment, the severe form of ulcerative colitis is indicative of MR-UC.
摘要翻译： 公开了预测患者中医学难治性溃疡性结肠炎（MR-UC）的发展的方法。在一个实施方案中，公开了通过确定一种或多种风险变异体的存在或不存在来预测个体中溃疡性结肠炎的方法，其中 一种或多种风险变体的存在表示严重和/或侵略性形式的溃疡性结肠炎。 在另一个实施方案中，严重形式的溃疡性结肠炎指示MR-UC。
-
公开(公告)号：US20120208900A1
公开(公告)日：2012-08-16
申请号：US13372359
申请日：2012-02-13
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156
摘要： The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.
摘要翻译： 本发明涉及通过确定一种或多种风险变体的存在或不存在来预测个体中严重形式的克罗恩病易感性的方法。 在一个实施方案中，风险变体包括遗传风险变体和临床危险因素的组合。 在另一个实施方案中，遗传风险变体位于IL12B遗传基因座。 在另一个实施方案中，克罗恩病的严重形式的特征在于快速进展到需要手术治疗的病症。
-
公开(公告)号：US09902996B2
公开(公告)日：2018-02-27
申请号：US13372359
申请日：2012-02-13
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156
摘要： The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.
-
公开(公告)号：US20120190698A1
公开(公告)日：2012-07-26
申请号：US13358424
申请日：2012-01-25
申请人： Marla Dubinsky , Dermot P. McGovern
发明人： Marla Dubinsky , Dermot P. McGovern
CPC分类号： A61K31/52 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates to methods of predicting therapeutic efficacy of thiopurines in an individual by determining the presence of one or more risk variants. In one embodiment, the effective therapeutic efficacy of thiopurines is determined by the presence of risk variants at the genetic loci of HLA-DRB1, CREM, TAGAP, PLCL1, GPX4, SBNO2, MEF2A and/or LYSMD4. In another embodiment, the risk variants are located at the genetic loci of ARL4C, IL1R2, JAK2, 19q13, CARD9, SNAPC4, and/or 8q24. In another embodiment, the individual is has been diagnosed with inflammatory bowel disease.
摘要翻译： 本发明涉及通过确定一种或多种风险变体的存在来预测硫嘌呤在个体中的治疗功效的方法。 在一个实施方案中，硫嘌呤的有效治疗功效是通过在HLA-DRB1，CREM，TAGAP，PLCL1，GPX4，SBNO2，MEF2A和/或LYSMD4的遗传基因座处存在风险变体来确定的。 在另一个实施方案中，风险变体位于ARL4C，IL1R2，JAK2，19q13，CARD9，SNAPC4和/或8q24的遗传基因座。 在另一个实施方案中，个体已被诊断患有炎症性肠病。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.029 秒)
